Despite the problems cited above, endostatin has shown potential as an alternative therapy to anti-VEGF monoclonal antibodies for its effectiveness in advanced stages of cancer, mainly in the context of NSCLC, showing similar efficacy and a good safety profile. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.